medigraphic.com
ISSN 2448-8720 (Print)
Organo Oficial de la Secretaria de Salud de Quintana Roo

2021, Number 45

<< Back Next >>

Salud Quintana Roo 2021; 14 (45)

Metabolic Syndrome at a hemodialysis ambulatory unit. Pilot study

May-Euán JF, Franco-Carrillo E, Can-Simá G, Us-Domínguez H, Otero-Soto R, Pool-Baas CG

Language: Spanish
References: 19
Page: 13-17
PDF size: 352.07 Kb.


ABSTRACT

Introduction. The present study aims to identify the percentage of metabolic syndrome in the hemodialysis unit of the Elvia Carrillo Puerto Hospital of the ISSSTE in Mérida, Yucatán. Material and methods. pilot, descriptive and cross-sectional study. The data were taken from patients attending the hemodialysis program at the Elvia Carrillo Puerto Hospital of the ISSSTE in Mérida, Yucatán. Each of the variables was collected from the patient's medical history, captured in the SPSS version 20 program, and descriptively analyzed. Results. 52.2% men, and 47.8% women participated; the median age was 58 years with a minimum of 30 and a maximum of 73. The 56.5% of the sample was diagnosed with metabolic syndrome. The 91.3% of the participants presented hypertension, 39.1% elevated triglycerides, 30.4% obesity, 30.4% decreased High Density Lipoproteins, and 26.1% hyperglycemia (56.5% diabetic). Discussion. People over 50 years of age, married and with basic education are sociodemographic conditions that predominated in our sample and also prevail in the majority of the population receiving Hemodialysis in Mexico. In other studies, as in the present investigation, hypertension is the most frequent component of metabolic syndrome. Conclusion. The percentage of metabolic syndrome was high, with hypertension as its main component. A longitudinal study is needed, to the extent possible multicenter, to confirm our findings and evaluate the consequences of Metabolic Syndrome in Yucatan’s receiving Hemodialysis.


REFERENCES

  1. Belarbia A, Nouira S, Sahtout W, Guedri Y, Achour A. Metabolic syndrome and chronic kidney disease. Saudi J Kidney Dis Transplant. 2015; 26(5):931.

  2. Gorsane I, Mahfoudhi M, Younsi F, Barbouch S, Ben Abdallah T. Impact of the components of metabolic syndrome on survival in a group of hemodialysis. Tunis Med. 2015; 93(12):777-82.

  3. Upala S, Sanguankeo A. Metabolic syndrome increases mortality risk in dialysis patients: A systematic review and meta-analysis. Int J Endocrinol Metabol. 2018; 16. Kowsar Medical Publishing Company;

  4. Kubrusly M, Oliveira CMC de, Simões PSF, Lima R de O, Galdino PNR, Sousa P de AF, et al. Prevalence of metabolic syndrome according to NCEPATP III and IDF criteria in patients on hemodialysis. J Bras Nefrol. 2015 Jan 1; 37(1):72-8.

  5. Alswat KA, Althobaiti A, Alsaadi K, Alkhaldi AS, Alharthi MM, Abuharba WA, et al. Prevalence of Metabolic Syndrome Among the End-Stage Renal Disease Patients on Hemodialysis. J Clin Med Res. 2017; 9(8):687-94.

  6. Saboya PP, Bodanese LC, Zimmermann PR, da Silva Gustavo A, Assumpção CM, Londero F. Síndrome metabólica e qualidade de vida: Uma revisão sistemática. Vol. 24, Rev Latino-Am Enfermagem. University of Sao Paulo, Ribeirao Preto College of Nursing Organisation; 2016.

  7. Wang J, Yue P, Huang J, Xie X, Ling Y, Jia L, et al. Nursing Intervention on the Compliance of Hemodialysis Patients with End-Stage Renal Disease: A Meta-Analysis. Blood Purification. S. Karger AG; 2018; 45:102-9.

  8. Norma Oficial Mexicana NOM-171-SSA1-1998, Para la práctica de hemodiálisis.

  9. Tratamiento sustitutivo de la función renal. Diálisis y Hemodiálisis en la insuficiencia renal crónica. México: Secretaría de Salud; 25 de septiembre 2014.

  10. Secretaría de Salud. Reglamento de la Ley General de Salud en Materia de Investigación para la Salud [Internet]. Ciudad de México; 2014. Available from: http://www.salud.gob.mx/unidades/cdi/nom/compi/rlgsmis.html

  11. Weltärztebund. WMA Deklaration von Helsinki -Ethische Grundsätze für die medizinische Forschung am Menschen. WMA-Generalversammlung. 2013; 35(53):1-10.

  12. Tamayo J. La enfermedad renal crónica en México. Hacia una política nacional para enfrentarla. México: Intersistemas; 2016.

  13. Barragán-Fuentes A, Laguna H, Gómez-de-Regil L. Perfil sociodemográfico de los usuarios del servicio de hemodiálisis del Hospital Regional de Alta Especialidad de la Península de Yucatán. Evid Méd Invest Salud. 2014 Jan 31; 7:4-9.

  14. Prasad GR. Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol. 2014; 3(4):210.

  15. Tu SF, Chou YC, Sun CA, Hsueh SC, Yang T. The prevalence of metabolic syndrome and factors associated with quality of dialysis among hemodialysis patients in Southern Taiwan. Glob J Health Sci. 2012; 4(5):53-62.

  16. Tsangalis G, Papaconstantinou S, Kosmadakis G, Valis D, Zerefos N. Prevalence of the metabolic syndrome in hemodialysis. Int J Artif Organs. 2007 Feb; 30(2):118-23.

  17. Bossola M, Giungi S, Tazza L, Luciani G. Is there any survival advantage of obesity in Southern European haemodialysis patients? Nephrol Dial Transplant. 2010; 25(1):318-9.

  18. Yen TH, Lin JL, Lin-Tan DT, Hsu CW. Association between body mass and mortality in maintenance hemodialysis patients. Ther Apher Dial. 2010; 14(4):400-8.

  19. Vogt BP, Ponce D, Caramori JCT. Anthropometric Indicators Predict Metabolic Syndrome Diagnosis in Maintenance Hemodialysis Patients. Nutr Clin Pract. 2016; 31(3):368-74.




2020     |     www.medigraphic.com